UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2011-07, Vol.22 (7), p.1622-1627

2011

Volltextzugriff (PDF)

Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma

Journal of clinical oncology, 2005-02, Vol.23 (4), p.694-704

2005

Volltextzugriff (PDF)

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Annals of oncology, 2015-08, Vol.26 (8), p.1667-1677

2015

Volltextzugriff (PDF)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Annals of oncology, 2013-11, Vol.24 (11), p.2892-2897

2013

Volltextzugriff (PDF)

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Leukemia, 2015-07, Vol.29 (7), p.1578-1586

2015

Volltextzugriff (PDF)

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

Annals of oncology, 2010-09, Vol.21 (9), p.1756-1764

2010

Volltextzugriff (PDF)

Novel induced-mesenchymal stem cells (i-MSCS) attenuate severity of ards in septic sheep

Cytotherapy (Oxford, England), 2021-05, Vol.23 (5), p.S33-S33

2021

Volltextzugriff (PDF)

Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness”

Annals of oncology, 2018-11, Vol.29 (11), p.2271-2271

2018

Volltextzugriff (PDF)

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Annals of oncology, 2012-09, Vol.23 (9), p.2356-2362

2012

Volltextzugriff (PDF)

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (7), p.613-619

2008

Volltextzugriff (PDF)

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

Bone marrow transplantation (Basingstoke), 2003-08, Vol.32 (4), p.405-410

2003

Volltextzugriff (PDF)

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Annals of oncology, 2001-01, Vol.12 (1), p.109-114

2001

Volltextzugriff (PDF)

Intensive conditioning regimen of etoposide followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (7), p.613

2008

Volltextzugriff (PDF)

Veltuzumab

Drugs of the future, 2011, Vol.36 (7), p.519

2011

Volltextzugriff (PDF)

Veltuzumab

Drugs of the future, 2011, Vol.36 (7), p.519

2011

Volltextzugriff (PDF)

Radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) does not preclude subsequent radiotherapy or other antilymphoma therapies: Updated safety and efficacy data

International journal of radiation oncology, biology, physics, 2004-09, Vol.60 (1), p.S545-S545

2004

Volltextzugriff (PDF)

Partial purification and characterization of particulate acid phosphatase of Leishmania donovani promastigotes

Comparative biochemistry and physiology. B, Comparative biochemistry, 1982, Vol.72 (4), p.581-590

1982

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

Novel induced-mesenchymal stem cells (i-MSCS) attenuate severity of ards in septic sheep

Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness”

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Intensive conditioning regimen of etoposide followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Veltuzumab

Veltuzumab

Radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) does not preclude subsequent radiotherapy or other antilymphoma therapies: Updated safety and efficacy data

Partial purification and characterization of particulate acid phosphatase of Leishmania donovani promastigotes

Suchergebnisse filtern